Treatment A: Acalabrutinib tablet + Treatment B: Acalabrutinib capsule
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence
Conditions
Bioequivalence
Trial Timeline
Feb 25, 2021 → May 10, 2021
NCT ID
NCT04768985About Treatment A: Acalabrutinib tablet + Treatment B: Acalabrutinib capsule
Treatment A: Acalabrutinib tablet + Treatment B: Acalabrutinib capsule is a phase 1 stage product being developed by AstraZeneca for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT04768985. Target conditions include Bioequivalence.
What happened to similar drugs?
1 of 1 similar drugs in Bioequivalence were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04768985 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence